Advanced Oncotherapy - Study showcases the potential superiority of LIGHT

Advanced Oncotherapy

28/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221128:nRSb7017Ha&default-theme=true

RNS Number : 7017H  Advanced Oncotherapy PLC  28 November 2022

 

 

28 November 2022

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Study showcases the potential superiority of LIGHT in treating breast cancer
patients

 

Study demonstrates that LIGHT proton minibeams could result in up to 99%
reduction in radiation dose to critical organs, the heart and lungs, compared
with cyclotron-generated protons

 

Findings expected to be presented at a leading medical conference in 2023

 

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation
proton therapy system for cancer treatment, is pleased to announce findings of
an important simulation study which suggests LIGHT will offer superiority in
the treatment of breast cancer. These results, coupled with the cost benefits
of LIGHT over cyclotron-based proton therapy, build the case for the increased
use of proton therapy for breast cancer patients, a large market that has
potential to be addressed by LIGHT.

 

The study, which was conducted by the Company, has subsequently been reviewed
by its research partner, the Cleveland Clinic, and is expected to be presented
at a leading medical conference during 2023. Such simulation studies are an
accepted practice in radiotherapy and have been shown to be highly accurate in
predicting tumour response and follow-up event rates(1).

 

The research compared treatment plans for breast cancer patients, created in
RayStation (RaySearch Labs AB, Stockholm), a treatment planning system, for
two digital anthropomorphic phantoms (digital human models), which differed in
body mass index and breast volume: a larger patient model - "50", and a
smaller patient model - "89". The aim of the research was to investigate the
relative doses to critical organs at risk ("OAR"), in particular the heart and
lungs in the case of breast cancer radiotherapy, for proton therapy with the
LIGHT system and LIGHT minibeams versus cyclotron-based proton therapy
systems. Reducing the collateral radiation dose delivered to the healthy
tissues in OAR is associated with a lower toxicity burden to patients. In
addition, the research assessed whether treating breast cancer patients with
LIGHT in the upright position compared to traditional treatment in the supine
(lying down) position may offer further benefits to patients.

 

The findings from the simulation study imply that the LIGHT beam spot size,
particularly LIGHT minibeams, is capable of delivering better results for OAR
preservation in patients with breast cancer while maintaining similar target
coverage compared with legacy cyclotron treatment. In addition, the study
showed that treating patients in an upright position, as the Company has
installed at its assembly site in Daresbury, Cheshire, UK, demonstrated
superior results compared with the supine position for whole breast radiation.
The superiority of the upright treatment position is attributed to the greater
physical separation between the heart and the breast in comparison to the
supine position. Specifically, the LIGHT minibeam system was found to reduce
the OAR doses by up to 99% compared with the cyclotron-generated proton beams.
As seen in Table 1 below, the OAR dose reductions were greatest for whole
breast irradiations in the upright position and the LIGHT minibeams were shown
to reduce OAR dose in all of the modelled situations.

 

Table 1: Maximum small volume OAR dose reduction for LIGHT proton minibeams
vs. cyclotron proton beams

 

                                            % heart dose reduction  % lung dose reduction
 Patient "50" model supine whole breast     98                      96
 Patient "50" model supine partial breast   81                      83
 Patient "50" upright whole breast          98                      96
 Patient "50" upright partial breast        70                      83

 Patient "89" model supine whole breast     99                      98
 Patient "89" model supine partial breast   25                      75
 Patient "89" model upright whole breast    99                      99
 Patient "89" model upright partial breast  65                      68

 

Breast cancer is the most common malignancy affecting women worldwide,
representing about 25% of all cancers in women(2). Radiotherapy is commonly
used as adjuvant to breast conserving surgery. To date, conventional photon
radiotherapy has widely been used to treat breast cancer but can result in
significant doses to surrounding organs such as the lungs and heart,
especially increasing the risk of coronary heart disease. As previously
published by the Particle Therapy Cooperative Group ("PTCOG") Breast Cancer
Subcommittee, proton therapy has been shown to reduce the dose to non-target
structures while optimising target coverage(3). However, PTCOG noted that
there remains additional financial costs associated with proton therapy, which
the Company believes could be addressed by the LIGHT system as a cost
effective method of delivering proton therapy to patients with breast cancer.

 

Dr. Jonathan Farr, Chief Clinical Officer of Advanced Oncotherapy, said:

 

"We are excited to announce the results of a study conducted by the Company
and reviewed by our research partner, the Cleveland Clinic, which showcases
the potential superiority of using the LIGHT system in breast cancer
treatment, the most common malignancy in women, versus a traditional cyclotron
source proton therapy system. The findings show that the LIGHT proton system
is ideally positioned to target such tumours while minimising damage to
surrounding healthy tissues, in particular, the heart and lungs. We look
forward to presenting data from this simulation at a leading medical
conference in 2023 and continuing to work with our research partners to
illustrate the clinical advantages of our LIGHT system to patients."

 

Notes

 

1 - Nat Rev Clin Oncol. 2013 January; 10(1): 27-40.
doi:10.1038/nrclinonc.2012.196.

 

2 - Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the
year 2020: An overview. Int J Cancer. 2021;149(4):778-789.

 

3 - Int J Radiat Oncol Biol Phys. 2021 October 01; 111(2): 337-359.
doi:10.1016/j.ijrobp.2021.05.110.

 

 

- ENDS -

 

 

 Advanced Oncotherapy plc                                  www.avoplc.com (http://www.avoplc.com)
 Dr. Michael Sinclair, Executive Chairman                  Tel: +44 (0) 20 3617 8728
 Nicolas Serandour, CEO

 Allenby Capital Limited (Nomad and Joint Broker)
 Nick Athanas / Piers Shimwell (Corporate Finance)         Tel: +44 (0) 20 3328 5656

 Amrit Nahal / Matt Butlin (Sales and Corporate Broking)

 SI Capital Ltd (Joint Broker)
 Nick Emerson                                              Tel: +44 (0) 1483 413 500
 Jon Levinson                                              Tel: +44 (0) 20 3871 4066

 FTI Consulting (Financial PR & IR)                        advancedoncotherapy@fticonsulting.com
                                                           (mailto:advancedoncotherapy@fticonsulting.com)
 Simon Conway / Rob Winder                                 Tel: +44 (0) 20 3727 1000

 

Notes to Editors

 

About Advanced Oncotherapy Plc

 

Advanced Oncotherapy, a UK headquartered company with offices in London,
Geneva, The Netherlands and in the USA, is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced Oncotherapy's
team "ADAM," based in Geneva, focuses on the development of a proprietary
proton accelerator called, Linac Image Guided Hadron Technology (LIGHT).
LIGHT's compact configuration delivers proton beams in a way that facilitates
greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that
will enable them to treat cancer with innovative technology as well as
expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging
improvements in delivering proton therapy and actively seeks working
relationships with providers of these innovative technologies. Through these
relationships, the Company will remain the prime provider of an innovative and
cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESBRBTTMTTTTFT